Global patient safety nonprofit releases guidance for navigating supply chain disruptions caused by faulty syringes from China

News provided by

Apr 30, 2024, 08:53 ET

PLYMOUTH MEETING, Pa., April 30, 2024 /PRNewswire/ -- The FDA has been warning healthcare providers and the public about malfunctioning plastic syringes made in China since November 2023. The affected syringes are leaking, cracking, and breaking – putting patients at risk of receiving incorrect doses of medication, risking serious injury or death. While the FDA advises against using syringes manufactured in China, healthcare providers are working to secure safe alternatives which is a time consuming process fraught with inefficiencies and delays. Since most of the syringes imported to the U.S. are made in China, this issue has the potential to cause serious supply chain disruptions.

Global patient safety nonprofit releases guidance for navigating supply chain disruptions caused by faulty syringes from China

ECRI – one of the nation's largest patient safety nonprofits and the only independent evaluator of medical devices – has shared recommendations about mitigating the threat posed by these syringes since late last year. In an ECRI Exclusive Hazard Report from December 2023, ECRI advised its members to review their inventory of all plastic syringes to identify those made in China; contact vendors to request the original equipment manufacturer (OEM) identification; monitor recall notices to identify affected lots; and contact ECRI for help identifying alternative products or to request lot-specific quality testing of their syringe inventory.

ECRI recently released a comprehensive market analysis designed to help healthcare providers discontinue use of the affected syringes and secure safe alternatives. The report identifies the Key Performance Indicators (KPIs) of hundreds of comparable syringes to determine which are considered functionally equivalent. DOWNLOAD THE REPORT.

About ECRI:

ECRI is the world's only healthcare organization with the unique combination of capabilities including device evaluation in an independent testing lab; clinical safety expertise through the ECRI Patient Safety Office (PSO); alerts that track safety problems with medical devices long before they escalate to an FDA safety bulletin; and supply chain guidance for identifying functional equivalents in the marketplace.

SOURCE ECRI